We are no longer accepting Actos® cases.
The U.S. Food and Drug Administration (FDA) warns that use of the diabetes drug Actos® (pioglitazone) has been associated with serious health problems. A study published in the British Medical Journal found that patients who took Actos had an 83 percent increase in their risk of developing bladder cancer. Patients who used the drug for two or more years faced an 88 percent increased bladder cancer risk.
The FDA urges patients who have taken Actos to contact a medical professional immediately if they experience any of the following symptoms:
- Blood or red color in urine
- Urgent need to urinate or pain while urinating
- Pain in back or lower abdomen
Information about the risk of bladder cancer associated with Actos has been added to the Warnings and Precautions section of the label for pioglitazone-containing medicines, as well as the patient medication guide.
Different Pioglitazone Products, Same Bladder Cancer Risk
The active ingredient in Actos, pioglitazone, is also sold in combination with metformin (Actoplus Met®, Actoplus Met XR®) and glimepiride (Duetact®). Millions of patients have filled prescriptions for pioglitazone-containing products from retail pharmacies.
The personal injury lawyers at Cory Watson Attorneys are in the process of settling their clients’ Actos lawsuits.
*Cory Watson Attorneys is no longer accepting Actos Bladder Cancer cases.
Actos®, Actoplus Met®, Actoplus Met XR®, and Duetact® are registered trademarks of Takeda Pharmaceutical Company Limited and are used here only for the purpose of identifying the products in question. Cory Watson Attorneys is not associated with, sponsored by, or affiliated with the British Medical Journal, U.S. Food and Drug Administration, or Takeda Pharmaceutical Company Limited.